Study Analyzed AstraZeneca's (AZN) SYMBICORT(R) in Children with Persistent Asthma
More News related to AZN
- Organizational Changes at Silence Therapeutics
- Silence Therapeutics Announces Successful Opposition of Glover Patent
- AstraZeneca Supports New PhRMA Code on Interactions with Healthcare Providers: Will Ensure Compliance to Benefit Patient Care
- Deutsche Bank Downgrades AstraZeneca (AZN) to Hold
- MF Global Upgrades AstraZeneca plc (AZN) to Buy
More News related to Corporate News
- IAC (IACI) Announces Several Agreements for Spin-Off Plans
- IMAX Corporation (IMAX) Spikes Today As Its Theaters Are Sold Out Across The Country
- Motorola (MOT) Accuses Apple (AAPL) iPhone Exec of Taking Secrets -Bloomberg
- comScore (SCOR) Releases June U.S. Search Results (GOOG, YHOO, MSFT, IACI, TWX)
- Freeport (FCX) Spikes on Takeover Chatter; Vale (RIO) Denies Rumors
A new 12-week study(2) examined safety and efficacy measures of the maintenance combination asthma therapy, AstraZeneca (NYSE: AZN) SYMBICORT(R) (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol(2) in treating mild to moderate persistent asthma in children ages 6 to 15 years old(2) who were previously treated with an inhaled corticosteroid (ICS).(2) Of note, the study included efficacy assessments of nighttime symptoms, nighttime rescue medication use and rescue medication-free days in patients taking SYMBICORT compared to those taking formoterol dry powder inhaler (DPI) or budesonide pressurized metered-dose inhaler (pMDI). Results were presented today at the International Conference of the American Thoracic Society held in Toronto, Canada, May 16-21, 2008.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.29Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
